Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLL

Dr. Jeffrey Jones on Idelalisib Combinations in CLLПодробнее

Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLLПодробнее

Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLLПодробнее

Dr Jones Discusses ibrutinib/bendamustine/rituximab combination for CLLПодробнее

Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLLПодробнее

Dr Jeffrey Jones (Abstract S429)Подробнее

OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLLПодробнее

Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLLПодробнее

Rituximab, Obinutuzumab, and Ofatumumab in CLLПодробнее

Idelalisib for Previously Treated CLLПодробнее

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLLПодробнее

Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLLПодробнее

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLLПодробнее

Idelalisib in Chronic Lymphocytic LeukemiaПодробнее

Dr. Furman on the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLLПодробнее

Jeffrey Jones Discusses Nurses' Impact on Patient ComplianceПодробнее

Dr. Jones on Studying Venetoclax in R/R CLLПодробнее

Approaches to overcome side effects of idelalisib for follicular lymphomaПодробнее

Second Interim Phase 3 Study of Idelalisib /Rituximab for Relapsed Chronic Lymphocytic LeukemiaПодробнее